BioSpace News Archive

Biotech Beach

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and precisely deliver therapeutic doses over months or years through a single device.

January 4, 2024
·
11 min read
Biotech Bay

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO).

January 4, 2024
·
7 min read
Pharm Country

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

Indaptus Therapeutics, Inc. announces that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.

January 4, 2024
·
7 min read
Pharm Country

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

Lisata Therapeutics, Inc. today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination with the standard-of-care therapy in Oncology & Cancer Case Reports Journal on December 30, 2023.

January 4, 2024
·
7 min read
Pharm Country

ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024

ProPhase Labs, Inc. today reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.

January 4, 2024
·
4 min read
Drug Development

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Limited today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial.

January 4, 2024
·
4 min read
Business

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.

January 4, 2024
·
7 min read
Job Trends

Health Canada Approves Pfizer’s Bivalent Respiratory Syncytial Virus (RSV) Vaccine for Older Adults and Infants Through Maternal Immunization

Pfizer Canada ULC announces today the Health Canada approval of ABRYSVOTM, its bivalent Respiratory Syncytial Virus (RSV) vaccine.

January 4, 2024
·
5 min read
Lone Star Bio

FibroBiologics to Present at Biotech Showcase 2024

FibroBiologics, Inc. announced that it will attend the Biotech Showcase in San Francisco, CA from January 8-10, 2024.

January 4, 2024
·
3 min read
Biotech Bay

HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases

Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global.

January 4, 2024
·
2 min read